Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  CareDx, Inc    CDNA

CAREDX, INC

(CDNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

share with twitter share with LinkedIn share with facebook
share via e-mail
12/24/2019 | 07:01am EDT

BRISBANE, Calif., Dec. 24, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that, as an inducement material to entering into employment with CareDx, on December 23, 2019, 41 new employees were awarded grants of stock options to purchase 45,100 shares of common stock and restricted stock units (RSUs) for 13,100 shares of common stock. The stock options and RSUs were granted pursuant to the Company’s 2019 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Board of Directors in August 2019 under Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over four years, with 25% of the RSUs vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to continued service through each applicable vesting date. The stock options have an exercise price per share of $22.59, the closing price per share of CareDx’s common stock as reported on the Nasdaq Global Market on December 23, 2019. The stock options vest over four years with 25% of the stock options vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting on an equal monthly basis over the following 36 months, subject to continued service through each applicable vesting date.

CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: www.CareDx.com.

Forward-looking Statements:
This press release includes forward-looking statements, including statements regarding CareDx’s employees and equity plans. These forward-looking statements are based upon information that is currently available to CareDx, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with CareDx’s employees and equity plans, and additional risks set forth in CareDx’s filings with the Securities and Exchange Commission. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer, CareDx, Inc.
415-287-2393
sking@caredx.com

Investor Relations
Greg Chodaczek
646-924-1769
investor@caredx.com

Primary Logo


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CAREDX, INC
03/20REPEAT - NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted Af..
GL
03/20NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted After Anti-..
AQ
03/20NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted After Anti-..
GL
03/17CAREDX LAUNCHES REMOTRAC : Home-Based Monitoring of Transplant Patients
GL
03/12CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney..
GL
03/05CareDx Brings Personalized Care to Transplant with the Launch of KIRA Immuno-..
GL
02/28CareDx to Participate in Upcoming Investor Conferences
GL
02/28CAREDX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/27CAREDX : 4Q Earnings Snapshot
AQ
02/27CAREDX, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
Financials (USD)
Sales 2020 167 M
EBIT 2020 -21,6 M
Net income 2020 -20,1 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -48,9x
P/E ratio 2021 885x
Capi. / Sales2020 5,29x
Capi. / Sales2021 4,08x
Capitalization 885 M
Chart CAREDX, INC
Duration : Period :
CareDx, Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CAREDX, INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 45,00  $
Last Close Price 20,64  $
Spread / Highest target 186%
Spread / Average Target 118%
Spread / Lowest Target 69,6%
EPS Revisions
Managers
NameTitle
Peter K. Maag Chairman & Chief Executive Officer
Reginald Seeto President & Chief Business Officer
Paul Ciccolella Senior Vice President-Global Operations
Michael Bell Chief Financial & Principal Accounting Officer
Robert N. Woodward Vice President-Research & Development
Sector and Competitors